Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments

References

• Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation. 2010;121:569–583.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail. 2014;2:1–14.
   PubMed Web of Science ®Google Scholar
• Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009;52:141–152.
   PubMed Web of Science ®Google Scholar
• National Patient-Centered Clinical Research Network. ADAPTABLE: The Aspirin Study. Washington (DC): Patient-Centered Outcomes Research Institute; [cited 2018 Oct 1]. Available from: www.pcornet.org/aspirin
   Google Scholar
• Leadbeater PD, Kirkby NS, Thomas S, et al. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost. 2011;9:2050–2056.
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Leadbeater PD, Chan MV, et al. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost. 2011;9:2103–2105.
   PubMed Web of Science ®Google Scholar
• Bhavaraju K, Georgakis A, Jin J, et al. Antagonism of P2Y₁₂ reduces physiological thromboxane levels. Platelets. 2010;21:604–609.
   PubMed Web of Science ®Google Scholar
• Baber U, Dangas G, Cohen DJ, et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. Am Heart J. 2016;182:125–134.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, et al. Working group on on-treatment platelet reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–2273.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125:1276–1287.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–1020.
   PubMed Web of Science ®Google Scholar
• Jeong YH, Tantry US, Gurbel PA. Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel. Expert Opin Pharmacother. 2012;13:1771–1796.
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KA, et al. TRILOGY ACS investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297–1309.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Erlinge D, Ohman EM, et al. TRILOGY ACS platelet function substudy investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. Jama. 2012;308:1785–1794.
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Rangé G, et al. ARCTIC investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100–2109.
   PubMed Web of Science ®Google Scholar
• Collet JP, Silvain J, Barthélémy O, et al. ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577–1585.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Bolognese L, Dudek D, et al. ACCOAST investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999–1010.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188–1199.
   PubMed Web of Science ®Google Scholar
• Storey RF, Bliden KP, Patil SB, et al. ONSET/OFFSET investigators. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56:185–193.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 steering committee and investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar
• [cited 2008 Jan 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf
   Google Scholar
• [cited 2018 Mar 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001241/WC500100539.pdf
   Google Scholar
• Montalescot G, van ‘T Hof AW, Lapostolle F, et al. ATLANTIC investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016–1027.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, White HD, Ohman EM, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013;382:605–613.
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Lansky AJ, et al. PROSPECT investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–235.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133–1142.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. Eur Heart J. 2016;37:1143–1144.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
   PubMed Web of Science ®Google Scholar
• Yeh RW, Kereiakes DJ, Steg PG, et al. DAPT Study investigators. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015;65:2211–2221.
   PubMed Web of Science ®Google Scholar
• Mann KG, Brummel K, Butenas S. What is all that thrombin for? J ThrombHaemost. 2003;1:1504–1514.
   PubMed Web of Science ®Google Scholar
• Silvain J, Collet JP, Nagaswami C, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011;57:1359–1367.
   PubMed Web of Science ®Google Scholar
• Yunoki K, Naruko T, Sugioka K, et al. Erythrocyte-rich thrombus aspirated from patients with ST-elevation myocardial infarction: association with oxidative stress and its impact on myocardial reperfusion. Eur Heart J. 2012;33:1480–1490.
   PubMed Web of Science ®Google Scholar
• Ardissino D, Merlini PA, Bauer KA, et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood. 2003;102:2731–2735.
   PubMed Web of Science ®Google Scholar
• Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61–68.
   PubMed Web of Science ®Google Scholar
• Undas A, Szułdrzyński K, Brummel-Ziedins KE, et al. Systemic blood coagulation activation in acute coronary syndromes. Blood. 2009;113:2070–2078.
   PubMed Web of Science ®Google Scholar
• Li YH, Teng JK, Tsai WC, et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol. 1999;33:1543–1548.
   PubMed Web of Science ®Google Scholar
• Merlini PA, Ardissino D, Bauer KA, et al. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 1997;17:1325–1330.
   PubMed Web of Science ®Google Scholar
• Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002;99:1053–1059.
   PubMed Web of Science ®Google Scholar
• Winn MJ, Jain K, Ku DD. Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol. 1993;22:754–760.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. TRACER investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20–33.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. TRA 2P–TIMI 50 steering committee and investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–1413.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bonaca MP, Braunwald E, et al. TRA 2°P-TIMI 50 steering committee investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: aprespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012;380:1317–1324.
   PubMed Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION. ZONTIVITY™ (vorapaxar) Tablets 2.08 mg*, for oral use; [cited 2018 Mar 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204886s000lbl.pdf
   Google Scholar
• Gurbel PA, Bliden KP, Turner SE, et al. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler Thromb Vasc Biol. 2016;36:189–197.
   PubMed Web of Science ®Google Scholar
• Williams MJ, Morison IM, Parker JH, et al. Progression of the culprit lesionin unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol. 1997;30:364–369.
   PubMed Web of Science ®Google Scholar
• Anand SS, Yusuf S, Pogue J, et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation. 1998;98:1064–1070.
   PubMed Web of Science ®Google Scholar
• Andreotti F, Testa L, Biondi-Zoccai GG, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519–526.
   PubMed Web of Science ®Google Scholar
• Testa L, Zoccai GB, Porto I, et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol. 2007;99:1637–1642.
   PubMed Web of Science ®Google Scholar
• Doraiswamy VA, Slepian MJ, Gesheff MG, et al. Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. Expert Rev Cardiovasc Ther. 2013;11:1259–1267.
   PubMedGoogle Scholar
• Oldgren J, Budaj A, Granger CB, et al. RE-DEEM investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, Phase II trial. Eur Heart J. 2011;32:2781–2789.
   PubMed Web of Science ®Google Scholar
• Goto M, Miura S, Suematsu Y, et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. Int J Cardiol. 2016;220:602–607.
   PubMed Web of Science ®Google Scholar
• Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111:625–633.
   PubMed Web of Science ®Google Scholar
• Spronk HM, de Jong AM, Crijns HJ, et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014;101:344–351.
   PubMed Web of Science ®Google Scholar
• Steg PG, Mehta SR, Jukema JW, et al. RUBY-1 investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541–2554.
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost C, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Becker RC, Bhatt DL, et al. APPRAISE steering committee and investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation. 2009;119:2877–2885.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. APPRAISE-2 investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.
   PubMed Web of Science ®Google Scholar
• Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1–16.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Jan 12]. Available from: https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf
   Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, et al. R ivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, Phase II trial. Lancet. 2009;374:29–38.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. ATLAS ACS 2–TIMI 51 investigators. N Engl J Med. 2012;366:9–19.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol. 2013;61:1853–1859.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Jan 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
   Google Scholar
• Roffi M, Patrono C, Collet JP, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:213–260.
   PubMed Web of Science ®Google Scholar
• Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389:1799–1808.
   Google Scholar
• Gurbel PA, Tantry US. GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet. 2017;389:1773–1775.
   PubMed Web of Science ®Google Scholar
• Chiarito M, Cao D, Cannata F, et al. Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: a systematic review and meta-analysis. JAMA Cardiol. 2018;3:234–241.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI steering committee and investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513–1524.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–2434.
   PubMed Web of Science ®Google Scholar